A Multicenter Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of the Combination of Rogaratinib and Copanlisib in Patients With FGFR-positive, Locally Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 06 Sep 2019
Price : $35 *
At a glance
- Drugs Copanlisib (Primary) ; Rogaratinib (Primary)
- Indications Carcinoma; Solid tumours; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ROCOCO
- Sponsors Bayer
- 03 Jul 2019 Planned End Date changed from 10 Mar 2021 to 29 Sep 2021.
- 03 Jul 2019 Planned primary completion date changed from 10 Mar 2021 to 29 Sep 2021.
- 03 Aug 2018 Planned End Date changed from 21 Apr 2021 to 10 Mar 2021.